Frail patients with atrial fibrillation who were switched to a newer NOAC agent had more bleeding than those left on older vitamin K antagonists, without any benefit in terms of thromboembolic events.
Medscape Medical News
VKA Therapy Beats Switch to NOAC in Frail AF Patients
